MX2022010780A - Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol. - Google Patents
Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol.Info
- Publication number
- MX2022010780A MX2022010780A MX2022010780A MX2022010780A MX2022010780A MX 2022010780 A MX2022010780 A MX 2022010780A MX 2022010780 A MX2022010780 A MX 2022010780A MX 2022010780 A MX2022010780 A MX 2022010780A MX 2022010780 A MX2022010780 A MX 2022010780A
- Authority
- MX
- Mexico
- Prior art keywords
- tapentadol
- dosage form
- prolonged release
- phosphoric acid
- acid salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20160419.6A EP3875077B1 (de) | 2020-03-02 | 2020-03-02 | Darreichungsform mit verlängerter freisetzung von tapentadolphosphorsäuresalz |
EP20160420.4A EP3875079A1 (de) | 2020-03-02 | 2020-03-02 | Darreichungsform mit verlängerter freisetzung von tapentadolphosphorsäuresalz |
PCT/EP2021/055025 WO2021175773A1 (en) | 2020-03-02 | 2021-03-01 | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022010780A true MX2022010780A (es) | 2022-09-26 |
Family
ID=74701506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022010780A MX2022010780A (es) | 2020-03-02 | 2021-03-01 | Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol. |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP4003318A1 (de) |
BR (1) | BR112022017700A2 (de) |
CO (1) | CO2022012567A2 (de) |
DE (1) | DE202021003994U1 (de) |
MX (1) | MX2022010780A (de) |
PE (1) | PE20230105A1 (de) |
WO (1) | WO2021175773A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20230105A1 (es) | 2020-03-02 | 2023-01-25 | Gruenenthal Chemie | Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
WO2006002886A1 (de) | 2004-07-01 | 2006-01-12 | Grünenthal GmbH | Gegen missbrauch gesicherte, orale darreichungsform enthaltend (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
CA2667925A1 (en) | 2006-10-27 | 2008-05-02 | Janssen Pharmaceutica N.V. | Dry granulated pharmaceutical compositions and methods for producing same |
BRPI0906467C1 (pt) | 2008-01-25 | 2021-05-25 | Gruenenthal Gmbh | forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada |
PE20190391A1 (es) | 2008-10-30 | 2019-03-13 | Gruenenthal Chemie | Formas de dosificacion del tapentadol novedosas y potentes |
WO2012010316A1 (en) | 2010-07-23 | 2012-01-26 | Grünenthal GmbH | Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
WO2012051246A1 (en) | 2010-10-12 | 2012-04-19 | Ratiopharm Gmbh | Tapentadol hydrobromide and crystalline forms thereof |
AU2014289187B2 (en) | 2013-07-12 | 2019-07-11 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
EP3027214A1 (de) | 2013-08-02 | 2016-06-08 | ratiopharm GmbH | Zusammensetzung mit tapentadol in gelöster form |
EP2942054A1 (de) | 2014-05-09 | 2015-11-11 | G.L. Pharma GmbH | Pharmazeutische Formulierung mit langsamer Wirkstoffabgabe |
DK3445742T3 (da) | 2016-04-19 | 2020-02-24 | Ratiopharm Gmbh | Krystallin tapentadolphosphat |
WO2018219897A1 (en) | 2017-05-29 | 2018-12-06 | Grünenthal GmbH | Multiparticulate oral dosage form providing prolonged release of tapentadol |
PE20230105A1 (es) | 2020-03-02 | 2023-01-25 | Gruenenthal Chemie | Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol |
-
2021
- 2021-03-01 PE PE2022001894A patent/PE20230105A1/es unknown
- 2021-03-01 MX MX2022010780A patent/MX2022010780A/es unknown
- 2021-03-01 BR BR112022017700A patent/BR112022017700A2/pt unknown
- 2021-03-01 EP EP21707730.4A patent/EP4003318A1/de active Pending
- 2021-03-01 WO PCT/EP2021/055025 patent/WO2021175773A1/en unknown
- 2021-03-01 DE DE202021003994.5U patent/DE202021003994U1/de active Active
-
2022
- 2022-09-02 CO CONC2022/0012567A patent/CO2022012567A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4003318A1 (de) | 2022-06-01 |
DE202021003994U1 (de) | 2022-04-12 |
WO2021175773A1 (en) | 2021-09-10 |
PE20230105A1 (es) | 2023-01-25 |
BR112022017700A2 (pt) | 2023-01-17 |
CO2022012567A2 (es) | 2022-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273194B2 (en) | Methods, compounds and preparations for the treatment of parainfluenza virus in patients with a deficiency in the immune system | |
MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
AU2017265011B2 (en) | Methods of administering high concentrations of nitric oxide | |
MX2020006650A (es) | Esketamina para el tratamiento de la depresión. | |
US20070110676A1 (en) | Compositions useful for prevention and treatment of common cold and influenza-like symptoms | |
MX362452B (es) | Tratamiento de degeneracion macular relacionada con la edad (amd) usando virus asociados con adeno (aav) sflt-1. | |
EP4378484A3 (de) | Formulierung für anti-alpha4beta7-antikörper | |
MX2022010780A (es) | Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol. | |
BR112017019343A2 (pt) | uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas | |
MX2008010155A (es) | Composiciones virucidales que contienen metal y sus usos. | |
TN2012000566A1 (en) | Dry powder formulation comprising an antimuscarinic drug | |
MX2016015417A (es) | Multiparticulas protegidas contra vertido de dosis etanolico. | |
MX360389B (es) | Formulacion farmaceutica o nutraceutica resistente a fluidos gastricos que comprende una o mas sales de acido alginico. | |
MX2019013372A (es) | Composiciones de neisseria meningitidis y sus metodos. | |
BR112015026053A2 (pt) | composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratamento de um paciente sofrendo ou susceptível a sofrer de um distúrbio respiratório e para fabricação de uma composição farmacêutica | |
MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
SI2646011T1 (en) | Procedures for reducing disturbance or compulsive overeating | |
MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
MX2021009219A (es) | Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria. | |
WO2012042197A3 (en) | Low dose pharmaceutical composition comprising zanamivir | |
IL303225A (en) | Reducing viral infections | |
MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. | |
KR20200052310A (ko) | 합성 라이신 유사체 및 모방체의 항바이러스 용도를 위한 방법 및 조성물 | |
MX2017013643A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. | |
Esteban-Sanchez | Lidocaine/prilocaine overdose |